Kestra Medical Technologies (NASDAQ:KMTS) Trading Down 9% – Time to Sell?

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) fell 9% during trading on Thursday . The stock traded as low as $20.50 and last traded at $20.1550. 96,304 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 266,652 shares. The stock had previously closed at $22.14.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Stifel Nicolaus set a $30.00 price target on shares of Kestra Medical Technologies in a report on Friday, December 12th. Piper Sandler boosted their target price on Kestra Medical Technologies from $27.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Wednesday, December 24th. BTIG Research initiated coverage on Kestra Medical Technologies in a research note on Tuesday, November 18th. They set a “buy” rating and a $32.00 price target for the company. Finally, The Goldman Sachs Group set a $24.00 price objective on Kestra Medical Technologies in a research note on Friday, January 16th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $29.00.

Kestra Medical Technologies Trading Down 13.3%

The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.47 and a current ratio of 5.47. The firm has a market cap of $1.12 billion and a P/E ratio of -6.06. The firm has a 50 day simple moving average of $24.78 and a 200 day simple moving average of $24.46.

Insider Buying and Selling

In other news, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $25.60, for a total transaction of $384,000.00. Following the completion of the transaction, the insider directly owned 379,786 shares in the company, valued at $9,722,521.60. The trade was a 3.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Traci S. Umberger sold 10,500 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $26.69, for a total value of $280,245.00. Following the completion of the sale, the insider owned 136,633 shares in the company, valued at $3,646,734.77. This trade represents a 7.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 55,500 shares of company stock worth $1,405,095 in the last ninety days. 3.60% of the stock is currently owned by insiders.

Institutional Trading of Kestra Medical Technologies

Institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. purchased a new position in shares of Kestra Medical Technologies during the fourth quarter worth about $239,000. Perceptive Advisors LLC purchased a new stake in shares of Kestra Medical Technologies during the 4th quarter valued at $7,558,000. Janus Henderson Group PLC bought a new stake in shares of Kestra Medical Technologies during the 4th quarter worth $300,000. Balyasny Asset Management L.P. raised its position in Kestra Medical Technologies by 80.6% during the fourth quarter. Balyasny Asset Management L.P. now owns 6,915 shares of the company’s stock valued at $183,000 after purchasing an additional 3,086 shares in the last quarter. Finally, Burkehill Global Management LP purchased a new position in shares of Kestra Medical Technologies in the 4th quarter worth about $1,326,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.